Skip to main content
Markets
/
CORONA · NSE
Market closedNSE | BSE
Loading live market indices
CO
NSE · Equity shares · Biotechnology & Drugs

Corona Remedies CORONA

NSE:INR 2,043.1Recorded price
BSE:INR 2,048.45Recorded price
Not available · Not available
Advanced chart
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeData unavailable
Day rangeINR 2,040 — INR 2,187.95
52-week rangeINR 1,336.95 — INR 2,261.4
VolumeNot available
Market cap12,527.15
P/E60.46
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,403.18
Net Income (INR Cr)185.12
P/E Ratio60.46
EPS32.74

Research path: Interpret Corona Remedies's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

AI and Advanced

AI analysis and Advanced tools for CORONA

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.
Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace
Interactive price chartInteractive chart loads when this section is visible.
Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…
Intelligence: activity, structure and reported deals

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company derivatives · NSE

CORONA futures & options

Expiry structure, futures, option chains and contract research.

Snapshot · timestamp unavailable
No observations

No matching contracts have verified observations for this filter.

DIRECTION · ACTIVITY · DISCLOSURES

CORONA Intelligence

Stored price, volume, causal structure and reported deals for this stock.

Market map
Checking research access…

Volume and pressure are activity estimates, not net money inflow. Futures and options retain their separate observations above.

Company reporting

Financial statements

IND AS · INR crore

Metric202620252024
Total Liabilities Shareholders' Equity1,205.14929.86830.58
Accumulated Depreciation Total-68.2-52.98-41.21
Other Liabilities Total66.0738.6132.04
Accrued Expenses0.050.470
Long Term Debt01667
Common Stock Total61.1661.1661.16
Other Current Assets Total42.668.3311.62
Prepaid Expenses5.7111.7810.59
Total Assets1,205.14929.86830.58
Current Portof LT Debt/Capital Leases19.1149.2169.31
Cash1.833.223.16
Total Equity746.86606.34480.41
Long Term Investments154.9927.2128.73
Retained Earnings(Accumulated Deficit)685.7545.18419.25
Total Common Shares Outstanding6.126.126.12
Property/Plant/Equipment Total-Gross502.46437.66352.81
Tangible Book Valueper Share Common Eq79.1471.1647.04
Total Liabilities458.28323.52350.17
Total Debt164.8586.23158.95
Short Term Investments2764.8265.89
Cashand Short Term Investments28.8368.0469.05
Total Receivables Net146.11121.24100.31
Notes Payable/Short Term Debt126.8600
Deferred Income Tax12.168.34.29
Accounts Receivable-Trade Net145.55118.2999.93
Property/Plant/Equipment Total-Net434.26384.68311.59
Total Current Liabilities361.17239.59224.19
Total Inventory125129.4898.35
Accounts Payable147.07143.52114.3
Other Currentliabilities Total68.0846.3940.59
Total Long Term Debt18.8837.0289.65
Intangibles Net262.83171.15192.69
Other Long Term Assets Total1.170.040.15
Note Receivable-Long Term3.587.917.5
Total Current Assets348.31338.87289.92
Capital Lease Obligations18.8821.0222.65
Fundamentals

Valuation and ratios

Valuation

PEG Ratio2.17

Price to Sale Ratio8.93

Margins

Operating Margin 12m17.29

Net Profit Margin 12m13.46

Yield

Dividend Yield %0.48

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk34.33

Analyst consensus

Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.
Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

CompanyPriceMarket capP/EResearch
Sun Pharmaceutical IndustriesINR 1,9444.66 L38.4—
Divi's LaboratoriesINR 8,291.552.20 L73.32—
Torrent PharmaceuticalsINR 4,9651.89 L72.73—
CiplaINR 1,4751.19 L27.57—
Zydus LifesciencesINR 1,106.251.10 L21.19—
Shareholding

Ownership

Promoter
69.00%
FII
3.63%
MF
12.50%
Other
14.87%
Corporate actions

Events

  1. board MeetingsQuarterly Results
  2. dividendRs.10.0000 per share(100%)Final Dividend
  3. board MeetingsAudited Results & Final Dividend
  4. board MeetingsQuarterly Results
  5. board MeetingsInter-alia, to consider and approve the financial results for the period ended September 30, 2025
Rusaka Markets Community

Discussion and sentiment for Corona Remedies

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Rusaka Markets Community

Community discussion loads as you approach this section.

Company profile

Business information

What the company does

Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.

Company facts

Industry
Biotechnology & Drugs
Sector
Biotechnology & Drugs
NSE Code
CORONA
BSE Code
544644
Questions

Stock FAQ

What is the symbol and ISIN of Corona Remedies?

Corona Remedies has the symbol CORONA and ISIN - INE02ZQ01018.

What is the latest recorded price of Corona Remedies?

The latest available recorded price of Corona Remedies is INR 2,043.10 as of 2026-08-06T20:57:34.864Z. This is a source-stamped snapshot, not a live quote.

What are the year high and year low of Corona Remedies?

Year high: INR 2,261.40. Year low: INR 1,336.95.

What is the market capitalization of Corona Remedies?

Market capitalization: INR 12,527.15 crore.

What is the P/E ratio of Corona Remedies?

P/E ratio: 60.46.

What is the dividend yield of Corona Remedies?

Dividend yield: 0.48%.

How is the financial performance of Corona Remedies based on revenue, net income, and EPS?

Revenue: INR 1,403.18 crore. Net income: INR 185.12 crore. EPS: INR 34.87.

What are the price-to-book and price-to-sales ratios of Corona Remedies?

Price-to-book ratio is unavailable in the current source. Price-to-sales ratio: 8.93.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.